Genmab kept by Merrill Lynch at buy

Danish biotech Genmab A/S was retained by Merrill Lynch & Co. at a buy rating, following the company's purchase of the licensing rights to a lymphoma drug from Medarex Inc. Genmab, based in Copenhagen, develops human antibodies for the treatment of life-threatening and debilitating diseases. On the Copenhagen exchange, Genmab shares on Friday gained DKK 1.00, or 0.93%, to close at DKK 108.00 on volume of 51,627 shares versus the three-month running average of 81,095.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.